PL378291A1 - Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin - Google Patents

Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin

Info

Publication number
PL378291A1
PL378291A1 PL378291A PL37829104A PL378291A1 PL 378291 A1 PL378291 A1 PL 378291A1 PL 378291 A PL378291 A PL 378291A PL 37829104 A PL37829104 A PL 37829104A PL 378291 A1 PL378291 A1 PL 378291A1
Authority
PL
Poland
Prior art keywords
cells
csf
dendritic
monocytes
dendritic cells
Prior art date
Application number
PL378291A
Other languages
English (en)
Other versions
PL209998B1 (pl
Inventor
Benjamin A. Tjoa
Marnix L. Bosch
Original Assignee
Northwest Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics, Inc. filed Critical Northwest Biotherapeutics, Inc.
Publication of PL378291A1 publication Critical patent/PL378291A1/pl
Publication of PL209998B1 publication Critical patent/PL209998B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL378291A 2003-02-27 2004-02-27 Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne PL209998B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45101503P 2003-02-27 2003-02-27
PCT/US2004/006119 WO2004076651A2 (en) 2003-02-27 2004-02-27 Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines

Publications (2)

Publication Number Publication Date
PL378291A1 true PL378291A1 (pl) 2006-03-20
PL209998B1 PL209998B1 (pl) 2011-11-30

Family

ID=32927693

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378291A PL209998B1 (pl) 2003-02-27 2004-02-27 Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne

Country Status (20)

Country Link
US (4) US8389278B2 (pl)
EP (1) EP1604016B1 (pl)
JP (1) JP4762887B2 (pl)
KR (2) KR101201875B1 (pl)
CN (1) CN1784488B (pl)
AT (1) ATE420946T1 (pl)
AU (2) AU2004214896A1 (pl)
BR (1) BRPI0407900A (pl)
CA (1) CA2517295C (pl)
CY (1) CY1109099T1 (pl)
DE (1) DE602004019057D1 (pl)
DK (1) DK1604016T3 (pl)
ES (1) ES2321939T3 (pl)
IL (1) IL170512A (pl)
MX (1) MXPA05009178A (pl)
NZ (1) NZ542071A (pl)
PL (1) PL209998B1 (pl)
RU (1) RU2364625C2 (pl)
TW (1) TW200506061A (pl)
WO (1) WO2004076651A2 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
JP5015601B2 (ja) * 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
KR20220113543A (ko) * 2005-12-08 2022-08-12 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
EP1806395A1 (en) * 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
KR100896747B1 (ko) 2007-05-30 2009-05-11 동아대학교 산학협력단 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
FR2940451B1 (fr) * 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
EP2427485B1 (en) * 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133 epitopes
WO2011011688A2 (en) * 2009-07-24 2011-01-27 Rhode Island Hospital DENDRITIC CELL VACCINES FOR ASPARAGINYL- β - HYDROXYLASE EXPRESSING TUMORS
CA2777400C (en) 2009-10-12 2018-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
RU2575978C2 (ru) * 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
RU2458985C1 (ru) * 2011-03-18 2012-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
DE13746292T1 (de) * 2012-02-10 2014-10-30 Hakushinkouseikai Foundation Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
WO2016011878A1 (zh) * 2014-07-23 2016-01-28 国家纳米科学中心 一种抑制肿瘤转移和治疗白血病的多肽和多肽复合物、其制备方法及其应用
CN104098652B (zh) * 2014-07-23 2016-11-09 国家纳米科学中心 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用
IL256522B2 (en) * 2015-06-30 2024-10-01 Northwest Biotherapeutics Inc Optimally activated dendritic cells that result in an enhanced or enhanced antitumor immune response
RU2749610C2 (ru) * 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
CN105483084A (zh) * 2016-01-04 2016-04-13 英普乐孚生物技术(上海)有限公司 肿瘤抗原靶向性dc细胞的制备方法
EP3810641A4 (en) 2018-06-19 2022-07-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. ONCOLYTIC VIRUS OR ANTIGEN PRESENT CELL MEDIATED CANCER THERAPY USING TYPE I INTERFERON AND CD40 LIGAND
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
EP3945815A4 (en) * 2019-04-03 2023-04-19 Akron Biotechnology, LLC CRYOPRESERVATION AND CELL CULTURE MEDIA
US20220273709A1 (en) * 2019-07-12 2022-09-01 Kyushu University, National University Corporation Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death
EP4061423A4 (en) * 2019-11-18 2023-12-06 Children's Medical Center Corporation HYPERACTIVE DENDRITIC CELLS FOR PERMANENT ANTITUMOR EFFECT ON ADOPTIONAL CELL TRANSFER BASIS
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
US20240207308A1 (en) * 2021-05-07 2024-06-27 NANOFAENTECH CO., Ltd. Method for culturing dendritic cells
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
US12584107B2 (en) * 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
US20230287080A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
CN118389430A (zh) * 2024-04-12 2024-07-26 广东壹加再生医学研究院有限公司 一种高抗肿瘤特异性dc-cik细胞的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3683956D1 (de) * 1985-06-11 1992-04-02 Us Commerce In einem serumfreien medium in suspension kultivierte humane monozyten.
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CA2459713C (en) * 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
CN1713951B (zh) * 2002-06-19 2010-05-26 西北生物治疗药物公司 切向流过滤设备和白细胞富集方法
MXPA05008486A (es) * 2003-02-10 2005-11-17 Northwest Biotherapeutics Inc Celulas presentadoras de antigeno cd14+ cultivadas.

Also Published As

Publication number Publication date
AU2010201319A1 (en) 2010-04-29
EP1604016B1 (en) 2009-01-14
JP4762887B2 (ja) 2011-08-31
US20210102169A1 (en) 2021-04-08
WO2004076651A3 (en) 2005-03-10
US20130273654A1 (en) 2013-10-17
US20040203143A1 (en) 2004-10-14
TW200506061A (en) 2005-02-16
ES2321939T3 (es) 2009-06-15
CA2517295C (en) 2016-01-12
EP1604016A4 (en) 2006-03-08
JP2006519021A (ja) 2006-08-24
WO2004076651A2 (en) 2004-09-10
DE602004019057D1 (de) 2009-03-05
US10731130B2 (en) 2020-08-04
KR20050107471A (ko) 2005-11-11
CY1109099T1 (el) 2014-07-02
NZ542071A (en) 2007-11-30
BRPI0407900A (pt) 2006-03-21
AU2004214896A1 (en) 2004-09-10
RU2364625C2 (ru) 2009-08-20
US11827903B2 (en) 2023-11-28
ATE420946T1 (de) 2009-01-15
IL170512A (en) 2013-12-31
PL209998B1 (pl) 2011-11-30
US8389278B2 (en) 2013-03-05
EP1604016A2 (en) 2005-12-14
HK1086597A1 (en) 2006-09-22
CN1784488B (zh) 2010-07-28
MXPA05009178A (es) 2006-03-08
US20160024472A1 (en) 2016-01-28
US9102917B2 (en) 2015-08-11
KR101201875B1 (ko) 2012-11-15
AU2010201319B2 (en) 2012-09-06
CA2517295A1 (en) 2004-09-10
RU2005129561A (ru) 2006-03-10
KR20110106474A (ko) 2011-09-28
DK1604016T3 (da) 2009-05-18
CN1784488A (zh) 2006-06-07

Similar Documents

Publication Publication Date Title
PL378291A1 (pl) Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin
Zhang et al. Role of TCF‐1 in differentiation, exhaustion, and memory of CD8+ T cells: A review
Li et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway
Khosravi et al. Induction of CD4+ CD25+ FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation
Đokić et al. Mesenchymal stem cells from periapical lesions modulate differentiation and functional properties of monocyte‐derived dendritic cells
SG152273A1 (en) Pdx1 expressing endoderm
SG149061A1 (en) Definitive endoderm
CN116004533B (zh) iNKT细胞的激活扩增方法及其培养基组合
Holtick et al. Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells
WO2012118349A3 (ko) 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
EP2484759A3 (en) Methods of refolding mammalian glycosyltransferases
O'Connell et al. Type‐1 polarized nature of mouse liver CD8α–and CD8α+ dendritic cells: tissue‐dependent differences offset CD8α‐related dendritic cell heterogeneity
WO2001085920A3 (en) Compositions and methods for producing antigen-presenting cells
CA2510596A1 (en) Dendritic cell line
EP2377922A3 (en) PDX1 expressing endoderm
WO2005023982A3 (en) Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients
GanjiBakhsh et al. Mixture of fibroblast, epithelial and endothelial cells conditioned media induce monocyte-derived dendritic cell maturation
AU8478601A (en) Methods for culturing human lung mast cells and uses thereof
MX2007005928A (es) Metodos para la produccion de celulas de mamiferos.
Sánchez et al. Chemotherapy plus G‐CSF mobilized peripheral blood stem cell harvests from acute myeloid leukaemia patients contain large amounts of polyclonal myeloid linnegCD11cpos dendritic precursor cells
EP1927657A3 (en) Compositions and methods for producing antigen-presenting cells
CA2442300A1 (en) Cd8.alpha. + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
WO2004067697A3 (en) Icos+ suppresser t cells
Liotta et al. IL-4 is crucial for the in vitro generation of mature dendritic cells obtained from human cord blood CD34^ sup+^ precursors